Monte Rosa Therapeutics Inc. followed up December’s positive prostate cancer data with strong interim findings from a phase I ...
The U.S. FDA’s September 2022 final guidance for clinical decision support (CDS) systems set a dismal record for pushback, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback